Printer Friendly

LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED

 LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED
 SAN DIEGO, April 2 /PRNewswire/ -- La Jolla Pharmaceutical Co.


announced today that it received notice of allowance from the U.S. Patent Office of a patent concerning its drug candidate for Systemic Lupus Erythematosus (SLE) based on the company's core technology of "B-Cell tolerance" for arresting the synthesis of antibodies. In SLE patients, anti-DNA antibodies are a hallmark of the disease and are considered to be responsible for chronic kidney disease. SLE is a debilitating, life-threatening disease that affects more than 200,000 individuals in the United States.
 Joseph Stemler, the company's president, commented, "We are very pleased that this patent will issue shortly. It is the first of a group of pending applications covering the structure of tolerogens and the composition of our Lupus compound."
 La Jolla Pharmaceutical Co. was established in 1989 to develop products based on its proprietary antigen-polymer conjugate technology to treat antibody-mediated diseases. The company is privately held and is headquartered in San Diego.
 -0- 4/2/92
 /CONTACT: Andrew Wiseman of La Jolla Pharmaceutical, 619-452-6600/ CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU:


AL -- SD001 -- 4214 04/02/92 09:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 2, 1992
Words:195
Previous Article:FLUOR CORP. ANNOUNCES REPURCHASE OF GREENVILLE CENTRE I
Next Article:SHOPKO STORES REPORTS RECORD FOURTH QUARTER AND YEAR-END RESULTS
Topics:


Related Articles
LIDAK PHARMACEUTICALS RECEIVES NOTICES OF ALLOWANCE ON TWO U.S. PATENTS FOR THE TREATMENT OF ARTHRITIS
IDEC PHARMACEUTICALS RECEIVES NOTICE OF U.S. PATENT ALLOWANCE FOR PANEL OF ANTIBODIES TO TREAT LYMPHOMA
IDEC PHARMACEUTICALS RECEIVES NOTICE OF U.S. PATENT ALLOWANCE FOR MELIMMUNE(TM)-2 CANCER VACCINE: THERAPEUTIC TO TREAT MELANOMA
LA JOLLA PHARMACEUTICAL ALLOWED PATENT FOR LUPUS TREATMENT
LIDAK RECEIVES EUROPEAN PATENT FOR LIDAKOL
LIDAK PHARMACEUTICALS RECEIVES EXPANDED PATENT COVERAGE ON TOPICAL LIDAKOL(TM) CREAM
La Jolla Pharmaceutical Awarded Third U.S. Patent For Lupus Drug
La Jolla Pharmaceutical receives patent on stroke treatment.
La Jolla Pharmaceutical receives Riquent composition of matter patents in Europe and China.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters